Measurable Residual Disease (MRD) in AML and ALL

Measurable Residual Disease (MRD) in AML and ALL

HMP CME

1 month
7 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the 'Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges' symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses the use of MRD as a target for the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). © 2019 Imedex, an HMP Company

Up Next Autoplay